To evaluate, in different models, the ability of TRAP derived immunogens to elicit protective immunity against a challenge with Plasmodium sporozoites.
It is anticipated that these experiments will allow us to select an appropriate delivery system for TRAP derived immunogens inducing both humoral and cell mediated cytotoxic immunity. This information will provide the rationale for developing an experimental TRAP vaccine for human trials.
* Selection of delivery systems for inducing humoral immunity and specific CTLs against TRAP. Few antigen delivery systems, have been shown to induce both humoral immunity and specific CTLs, these include: recombinant vaccinia viruses; lipidic adjuvants; naked DNA; listeriolysin O (LLO) of L. monocytogenes. We will compare the relative efficacy of these delivery systems to induce an appropriate immune response against P. berghei TRAP immunogens containing B cell, Helper and CTL epitopes. Cell lines will stably transfected with a series of DNA vectors inducing the expression of progressively deleted PbTRAP constructs.
* Analysis of TRAP epitopes variability among P. falciparum isolates. Polymorphisms of immunologically relevant epitopes will render problematic the use of TRAP for the development of a vaccine. A total of one hundred blood samples will be collected from different locations of endemic areas in Mali at different time points during the malaria transmission season. Parasite DNA will be extracted from bloodspots and amplified with combinations of primers generating sequences of immunologically relevant T and B cell epitopes permitting direct DNA sequencing to look for mutations.
* Cloning of TRAP homologues from P. knowlesi, P. cynomolgi and P. fragile. There are no perfect host systems that can be used to model P. falciparum infection in humans. Aotus and Saimiri genera are variably susceptible to blood stage infections from a limited range of adapted parasite species, a challenge model with Aotus is limited to the use of particular monkey subspecies (Aotus lemurinus) and to a particular parasite strain (P. falciparum St. Lucia). Specific PCR products will be generated from parasite DNA using primers for regions of TRAP that are conserved between the Plasmodium species. Labelled PCR products will be used as probes to screen lambda gt 10/lambda gt 11 genomic libraries developed from DNA of P. knowlesi, P. cynomolgi and P. fragile.
* Evaluation of experimental induced PfTRAP immunity against Plasmodium sporozoite challenge. The TRAP gene from the St. Lucia strain will be amplified in PCR experiments, cloned and sequenced. A cohort consisting of 10 adult animals of either sex will be randomly assigned to three experimental groups of five animals each. The two groups of monkeys will be immunized with constructs generated using either St. Lucia TRAP or a polymorphic PfTRAP variant. After thorough analysis of humoral and cellular responses all the monkey cohorts will be challenged with 20,000 St. Lucia sporozoites. Monkeys will be observed daily for parasitemia.
Fields of science
- medical and health scienceshealth sciencesinfectious diseasesmalaria
- natural sciencesbiological sciencesmicrobiologyvirology
- natural sciencesbiological sciencesgeneticsDNA
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Call for proposalData not available
Funding SchemeCSC - Cost-sharing contracts
See on map
2288 GJ Rijswijk Zh
See on map
OX3 9DU Oxford
See on map